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Rat int erleukin-2-activated natural killer (A-NK) 
cell-mediated lysis is determined by the presence 
of CD18 on A-NK cells and the absence of major 
histocompatibility complex class I on target cells 
The precise mechanism by which target cells are recognized and subsequently 
lysed by interleukin-2-activated natural killer (A-NK) cells is poorly understood. 
In this study the role of major histocompatibility complex (MHC) class I and 
adhesion molecules in the recognition and lysis of tumor cells was investigated in a 
syngeneic Wag rat model. Preincubation of tumor cells with F(ab’)Z fragments of 
anti-MHC class I monoclonal antibody (mAb) OX18 strongly enhanced the 
A-NK cell-mediated lysis. Also normal syngeneic cells such as T cells and A-NK 
cells became highly sensitive for lysis by A-NK cells after preincubation with mAb 
OX18.Two other mAb against MHC class I had no effect on lysis of target cells. 
These data indicate that masking of MHC class I on syngeneic tumor and normal 
cells by mAb OX18 is sufficient for A-NK cells to recognize target cells as 
non-self, resulting in lysis. In addition,we found that the presence of mAb against 
the 82 (CD18)-integrins blocked the lysis of all tumor cell lines by A-NK cells in 
Wr-release assays, also when target cells were preincubated with mAb 0x18.  
Because of the absence of CD18 on most tumor cells we concluded that a 
CD18-associated integrin on A-NK cells is essential for lysis of target cells. These 
results show that in this syngeneic rat model CD18 on A-NK cells together with 
MHC class I on tumor cells determine A-NK cell-mediated lysis. Furthermore,we 
hypothesize that the anti-MHC class I OX18 recognizes an epitope on rat MHC 
class I which is, or is very close to, the restriction element determining A-NK 
cell-mediated lysis. 
1 Introduction 
NK cells are characterized as large granular lymphocytes 
which are able to lyse virally infected cells and some tumor 
cells without prior sensitization. Several molecules have 
been described to be involved in the binding and recogni- 
tion of target cells by NK cells. Adhesion molecules have 
been demonstrated to be responsible for the binding 
between NK cells and target cells. Especially the CD18- 
associated integrins LFA-1 (CDlla), CR3 (Complement 
Receptor 3) (CDllb), p150,95 (CDllc) and CD2, present 
on NK cells and ICAM-1 (CD54) and LFA-3 (CD58), 
present on target cells are described to be involved in NK 
cell-mediated lysis of allogeneic target cells [l]. IL-2- 
activated NK (A-NK) cells show an enhanced expression of 
the CD18-associated integrins and CD2,which results in an 
enhanced binding between the A-NK and target cells [2,3]. 
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Furthermore, MHC class1 on target cells has been de- 
scribed to affect NK cell recognition and/or lethal hit 
delivery. In a variety of experimental systems NK cells have 
been shown to recognize and eliminate target cells which 
fail to express “self” MHC class I (“missing self” hypothe- 
sis) [4]. 
In the present study the “missing self” hypothesis was 
tested in a syngeneic Wag rat tumor model, using A-NK 
cells as effector cells and tumor and normal cells as target 
cells. Furthermore, we investigated the involvement of 
adhesion molecules in the A-NK cell-mediated lysis of 
target cells. For this study we used mAb against several 
adhesion molecules and mAb against MHC class I. We 
demonstrate here that CD18 plays a major role in the rat 
A-NK cell-mediated lysis of syngeneic target cells and that 
masking of MHC class I on target cells by anti-MHC class I 
mAb OX18 is sufficient for rat A-NK cells to lyse syngeneic 
target cells. 
2 Materials and methods 
2.1 Antibodies 
The anti-rat mAb OX18 [5,6], U9F4 [7], F16.4.4.11 (F16) 
[8] (all anti-MHC class I), WT.3 (anti-CDlS), WT.l (anti- 
CDlla ,  LFA-l), 1A29 (anti-ICAM-1) [9, lo], OX42 (anti- 
CDllb/c) [ l l ] ,  ED7, ED8 (CDllb) [12, 131, and R73 
(anti-ap-Tcell receptor) [14] were used in this study. All 
antibodies were of the IgGl isotype, except U9F4 and 
WT.l, which were of the IgG2a subclass. 0x18,  F16.4.4 
and OX42 were purchased from ECACC (Porton Down, 
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Salisbury, GB). U9F4 was kindly provided by Dr. F.Thielen 
(Gaubius Institute, TNO, Leiden, The Netherlands), ED7 
and ED8 were kindly provided by Dr. J. G. M. C. 
Damoiseaux and Dr. C. D. Dijkstra, Vrije Universiteit, 
Amsterdam, The Netherlands. R73 was a gift from Dr. T. 
Hiinig (Ludwig Maximilians University, Munich, FRG). 
2.2 Production of F(ab')* fragments of OX18 
F(ab')z fragments of OX18 were obtained by pepsin 
digestion of OX18 at 10 mg/ml in 0.1 M citrate buffer (pH 4) 
in the presence of pepsin attached to 4% cross-linked 
beaded agarose (100 U/10 mg protein) (Sigma, St. Louis, 
MO), for 15 h at 37°C. After incubation the sample was 
centrifuged for 5 min at 7000 x g and the supernatant 
containing the F(ab')2 fragments was separated from the 
pellet containing the pepsin-agarose beads. The pH of the 
supernatant was adjusted to 7 with 3 M Tris-HC1 (pH 8.5). 
The F(ab')2 fragments were separated from intact IgG by 
affinity chromatography using a protein A column. The 
purity of F(ab');! fragments was determined by SDS-PAGE 
under non-reducing conditions. 
2.3 Tumor cell lines 
CC531, a Wag rat colon carcinoma [15], and MCR86 and 
WRM, both Wag rat breast adenocarcinomas, were main- 
tained as adherent cultures in culture medium consisting of 
RPMI-1640 medium (Gibco, Paisley, Scotland), supple- 
mented with 10% heat-inactivated FCS (Gibco), 2 mM 
L-glutamine, 50 pg/ml streptomycin and 50 Ulrnl penicillin. 
L4415, a Wag rat immatureT cell leukemia was passaged in 
vivo through intravenous (in tail vein) inoculation [16]. A 
large stock was prepared from spleens of tumor-injected 
animals and stored in liquid nitrogen. 
2.4 Preparation of A-NK cells and T cells 
A-NK cells and T cells were cultured from spleens of Wag 
rats according to protocols described before [17,18]. A-NK 
cells obtained were > 98% NKR-P1 (rat NK marker) 
positive and < 1% TcR positive. T cells were >98% TcR 
positive. 
2.5 Flow cytometry 
Briefly, tumor cells (5  x los) were subsequently incubated 
(30 min, 4 "C) with a saturating amount of one of the mAb 
and then with a predetermined optimal dilution of a 
fluorescein isothiocyanate-labeled goat anti-mouse anti- 
body (SBA, Birmingham, AL). Fluorescence analysis was 
performed using a FACScan flow cytometer (Becton Dick- 
inson, Mountain View, CA). 
2.6 %3-release assay 
Four-hour 51Cr-release assays were performed essentially 
as described earlier [17]. Target cells (0.5 X lo6) were 
incubated with either 1 pg OX18 mAb, F(ab')2 fragments 
of 0x18,  U9F4 mAb, F16 mAb, or no mAb (as control) for 
30 min at 4"C, before labeling with 51Cr. Where indicated, 
one of the mAb against adhesion molecules were present 
during the assay (final concentration 5 pg/ml). None of the 
mAb affected the spontaneous release of the slCr-labeled 
target cells. For CC531 and MCR86 an incubation period of 
19 h was used [17]. Representative data out of at least three 
experiments are shown as percentage of specific 51Cr 
release which are means of triplicate wells. 
3 Results 
3.1 Expression of surface antigens by tumor cells and 
normal cells 
The expression of the surface antigens CD18, LFA-1, 
ICAM-1 and MHC class I on tumor cells and normal cells 
was measured by flow cytometry. It is shown that the tumor 
cell lines CC531, MCR86, WRM, and L4415 expressed 
ICAM-1 and that L4415 additionally expressed CD18 and 
LFA-1 (Fig. 1). A-NK cells were shown to express MHC 
T CELL 
Figure 1 .  Expression of MHC class I and adhe- 
sion molecules by tumor cells and normal cells. 
Tumor cell lines CC.531, MCR86,WRM, L441.5 
and normal cells (A-NK cells and Tcells) were 
15 stained by indirect immunofluorescence with - the following mAb: OX18 (anti-MHC class I); 1 WT.3 (anti-CD18); WT.l (anti-LFA-1); 1A2Y 
1 (anti-ICAM-1), and were subsequently ana- 
$ lyzed for fluorescence intensity by flow cytom- - etry as described in Sect. 2.5. As a control, cells 
were incubated with goat anti-mouse-FITC 
RELATIVE FLUORESCENCE INTENSITY only. 
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classI, CD18 and LFA-1, but not ICAM-1. Tcells 
expressed all markers shown: MHC class I ,  CD18, LFA-1 
and ICAM-1. Furthermore, we found that A-NK cells did 
not express other CD18-associated CD11-subunits 
(CDllblc) than LFA-1 (CDlla) (data not shown). 
3.2 Participation of adhesion molecules in the cytolysis 
of tumor cells by A-NK cells 
To assess the role of CD18-associated integrins in A-NK 
cell-mediated lysis, we evaluated the effect of anti-CD18 
(WT.3) on lysis of the tumor cell lines in %r-release assays. 
In the presence of this mAb against CD18, A-NK cell- 
mediated lysis of CC531 and LA415 was completely inhib- 
ited and the lysis of MCR86 and WRM was inhibited by 
more than 60% (Table 1). The involvement of CD18- 
associated CD11-subunits (CDlla/b/c) in A-NK cell- 
mediated lysis was investigated with mAb against CDl la  
(WT.l), CDllblc (0x42) and CDl lb  (ED7 and ED8). 
Table 1 shows that the presence of anti-CDlla or CDllblc 
did not have any effect on the A-NK cell-mediated lysis of 
CC531. Also mAb against the counterpart of CDllalc 
integrins ICAM-1 (1A29) had no effect on the lysis of the 
tumor cells by A-NK cells. 
Table 1. Lysis of tumor cells by A-NK cells in presence of mAb 
against adhesion moleculesa) 
Target % specific W r  release 
cells in presence of mAb reactive with 
Control LFA-1 CD18 ICAM-1 C D l l b k  
CC53 1 22 22 0 23 24 
MCR86 19 19 4 20 n.t.b) 
WRM 14 16 5 13 n.t. 
LA415 5 5 0  4 n.t. 
a) A-NK cells were incubated with tumor cells in the presence of 
mAb against LFA-1 (WT.l), CD18 (WT.31, ICAM-1 (1A29), 
C D l l b k  (OX42), or C D l l b  (ED7, ED8) in a 51Cr-release assay 
as described in Sect. 2.6. As control, the assay was performed 
without rnAb. 
b) n.t. = not tested. 
3.3 Involvement of MHC class I in the tumor cell lysis 
by A-NK cells 
To investigate the role of MHC class I in A-NK cell- 
mediated lysis, tumor cells were preincubated with mAb 
against MHC class I (0x18) and used as target cells in a 
51Cr-release assay. Fig. 2 shows that the lysis of all 0x18- 
preincubated tumor cells was highly increased in compari- 
son with the lysis of untreated tumor cells. Furthermore, 
addition of anti-CD18 mAb WT.3 completely blocked the 
enhanced lysis of the 0x18-preincubated tumor cells. To 
exclude that the enhancement of lysis was caused by ADCC 
we produced F(ab')2 fragments of 0x18. Fig. 3 A  shows 
one band at 150 kDa in the lane of total mAb 0x18. In the 
F(ab')2 lane a band of 100 kDa, but no band at 150 kDa 
could be detected, showing that the F(ab')2 fragments were 
free from total mAb. Subsequently, CC531 was preincu- 
bated with F(ab')2 fragments of OX18 and used as target 
cells for A-NK cell-mediated lysis. The F(ab')2 fragments 
% specific release 
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Figure 2. Effect of anti-CD18 mAb WT.3 and anti-MHC class I 
mAb OX18 on A-NK cell-mediated Iysis of tumor cells.Target cells 
were tumor cell lines CC531 (A), MCR86 (B) ,WRM (C) and L4415 
(D) without antibody (0) or preincubated with mAb OX18 and 
then tested in the absence (*) or the presence (0) of mAb WT.3 in a 
51Cr-release assay as described in Sect. 2.6. 
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Figure 3. A-NK cell-mediated lysis of CC531 preincubated with 
mAb OX18 or F(ab')z fragments of 0x18. (A) SDS-PAGE of 
F(ab')z fragments of OX18 under non-reducing conditions. Mole- 
cular weight of the bands is indicated in kDa. (B) CC531 target cells 
were preincubated with PBS (O), mAb OX18 (0) or F(ab')z 
fragments of OX18 (*). 
were shown to be as effective as intact mAb in enhancing 
the lysis of CC531 by A-NK cells (Fig. 3B). Therefore, 
ADCC could be excluded. 
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3.4 Lysis of syngeneic normal cells by A-NK cells 
Next, we investigated whether syngeneic normal cells could 
also be lysed by A-NK cells when MHC class I on these 
normal cells was masked by the anti-MHC class I mAb 
0x18. As syngeneic normal target cells we used A-NK and 
Tcells. No lysis of untreated A-NK cells and Tcells was 
detected (Fig. 4). However, when these cells were preincu- 
bated with the anti-MHC class I OX18 60% of the Tcells 
were lysed (Em ratio 20) and 35% of the A-NK cells were 
lysed (Emratio 20) by A-NK cells. Anti-CD18 mAb WT.3 
again completely blocked the lysis of these 0x18-preincu- 
bated target cells. 
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Figure 4. Effect of anti-CD18 mAb WT.3 and anti-MHC class I 
mAb OX18 on A-NK cell-mediated lysis of normal cells. A-NK 
cells were incubated either with normal target cells (A: A-NK cells; 
B: Tcells (0) or with normal target cells preincubated with mAb 
OX18 in the absence (*) or in the presence of mAb WT.3 (0) in a 
SICr-release assay as described in Sect. 2.6. 
4 Discussion 
The mechanism of target cell recognition by A-NK cells is 
still poorly understood. In this study we confirm the 
“missing self’ hypothesis proposed by Ljunggren and Karre 
[4] in a syngeneic rat model. We demonstrated that tumor 
cells are lysed by A-NK cells if MHC class I on the tumor 
cells is masked by the anti-MHC class I mAb 0x18. This 
effect of anti-MHC class I mAb on A-NK cell-mediated 
lysis of tumor cells has also previously been shown in mouse 
and human models [19-221. In addition, we show in this 
study that A-NK cells were able to kill not only tumor cells 
but also syngeneic normal cells when the “self” MHC class I 
molecules were masked by anti-MHC class I 0x18. Appar- 
ently, A-NK cells are triggered for lysis when cells fail to 
express “self” MHC class I, as predicted by the effector 
inhibition model [4]. A prerequisite is that binding of these 
target cells must be possible via a CD18-associated integrin 
on A-NK cells. 
In our blocking experiments we showed that CD18 was 
involved in A-NK-mediated lysk but we could not show 
ICAM-1 or a CD18-associated CDl l  to be involved. The 
mAb we used have already been described to block other 
specific cellular functions. The anti-LFA-1 mAb WT.l and 
the anti-ICAM-1 mAb 1A29 blocked T cell proliferation 
and Tcell-mediated lysis [lo, 231. Anti-CDllbk (ED7, 
ED8) were able to inhibit macrophage recruitment [13]. In 
agreement with our observations Beun et al. did not 
observe blocking of non-specific T cell-mediated lysis of 
tumor cells by these mAb [24]. Therefore, these results 
might suggest that in the rat, LFA-1 and its ligand ICAM-1 
are not involved in the process of target cell lysis by A-NK 
cells. Alternatively, it can not be excluded that the mAb 
against LFA-1 and ICAM-1 we used did not block the 
functional binding site of LFA-1 and ICAM-1 on A-NK and 
tumor cells. The latter possibility is more likely because in 
the human and mouse system the involvement of these 
adhesion molecules in A-NK-mediated lysis has been 
shown using antibodies against LFA-1 and ICAM-1 125, 
261. Other mAb against rat LFA-1 and ICAM-1, recogniz- 
ing other epitopes on these adhesion molecules have to be 
developed to investigate whether these adhesion molecules 
are really involved in A-NK-mediated lysis in the rat. 
The involvement of RT1 (MHC class I in the rat) in A-NK 
cell-mediated lysis was shown in an allogeneic rat model by 
Vaage et al. [27, 281. They showed that the RT1.C region 
has a predominant role in determining target cell suscepti- 
bility for rat NK alloreactivity. In our syngeneic model we 
show that masking of RT1 by intact IgG or F(ab‘)Z 
fragments of OX18 on target cells enhances rat A-NK 
cell-mediated lysis. MAb OX18 has been described to bind 
to determinants of RT1.A antigens [5], but also of the 
RT1.C antigens [6]. Apparently, by masking the RTl.A/C 
antigens on target cells the A-NK cells were not able to 
recognize the target cells as self, resulting in lysis of the 
target cell. Other anti-MHC class I mAb U9F4 and F16 did 
not increase the A-NK cell-mediated lysis of tumor target 
cells. Therefore, we hypothesize that the mAb OX18 
recognizes an epitope on rat histocompatibility RT1 which 
is, or is very close to, the restriction element which 
determines A-NK cell-mediated lysis. This restriction ele- 
ment could be RT1.A or RTl.C, but the studies described 
by Vaage et al. in an allogeneic rat model suggest that it is 
RT1.C [28]. Further studies, focussed on these RT1-genes, 
might solve the question which RT1-genes contain the 
restriction element for A-NK cell-mediated lysis in the rat. 
This syngeneic rat model and the A-NK-lysis modulating 
effect of the anti-MHC class I mAb OX18 presented here 
may be very useful in unravelling the precise mechanism of 
target recognition by A-NK cells. 
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